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Table 1. Clinical evolution  CIBMTR Pattern
Clinical Evolution Evaluation Method Cibmtr Pattern
Glucose 5 192mg/dL Acquired knowledgment + lab report Diabetes / hyperglycemia
Skin damage Physician and data manager discussion + lab report + acquired
knowledgment
Acute Skin GVHD, overall maxim grade II, stage 2
(25-50% of skin surface)
Mouth / GI Chronic GVHD Physician and data manager discussion + lab report + acquired
knowledgment
Chronic GVHD progressive, maximum grade: extensive,
overall severity: severe
Unremarkable mouth lichen Physician and data manager discussion + acquired knowledgment Are symptoms of chronic GVHD still present on the date
of actual contact?
Pleural effusion /
basilar consolidation
Physician and data manager discussion + acquired knowledgment Did the recipient develop non-infectious pulmonary
abnormalities?
RSV+ Lab report + acquired knowledgment Organism: RSV, Infection site: sinuses, date of diagnosis
Moderate ascites Physician and data manager discussion + lab report + acquired
knowledgment
Non-infectious liver toxicity (excluding GVHD)
S190 Oral Presentationspossible to get a conclusively and directly interpretation to be re-
ported on the standard CIBMTR data pattern.
Method: Study of a related allogeneic transplant case that we were
asked to do the Comprenhesive Report Form.
Case: Male, 53 years-old, MDS, HSCT infusion: 06/20/2009,
PBSC, HLA-identical sibling, Bu 1 Flu, ANC recovery: 05/07/
2009 and platelet recovery: 07/10/2009.
Results:Analyzing the chart, it’s seen that the interpretation of writ-
ten clinical data to the standard official CIBMTR forms requires
more than generalized information that are easily understood by
the clinical staff with their real and daily involvement with them
and the experience of practicing medicine. Data managers have
a ‘‘virtual relationship’’ with patients, no personal contact with
them and without scientific knowledgment to interpret certain infor-
mation and reports. What was concluded is that more detailed the
clinical outcome in the patient records, more support of clinical staff
and more acquired knowledgment by data managers, greater the ef-
ficiency in reporting data with a high degree of fidelity.
Feedback:During the relationship’s period between our Transplant
Center and CIBMTR we had a positive evolution of the way to deal
with transplant data. Physician’s and data managers’ relation had
global gains to our Center, working with the clinical outcome as
the primary source of data to be consulted and having footing for
this. The multidisciplinary team’s integration and the effort of the
medical directors, gave the data managers (including database per-
sonnel and a nurse) a day-by-day know-how to read clinical data
(not to interpret it, but the transcript it to CIBMTR standard) and
thus, gradually, the intervention of medical staff shall not be so nec-
essary. That is, reporting data to CIBMTR spawned to a natural evo-
lution of our Transplant Center, of the team (physicians, data
managers and nurse) and of the description and interpretation of
clinical information, resulting in the reliability of data, generating
a solid basis for prospective studies.99
PUBLICATION BIAS IN BLOOD AND MARROW TRANSPLANTATION: AN
ANALYSIS OF THE TANDEM MEETING ABSTRACTS
Paulson, K.1, Saeed, M.1, Mills, J.2, Cuvelier, G.D.E.1, Kumar, R.1,
Morcombe, K.1, Ramesar, K.1, Robinson, T.1, Szwajcer, D.1, Wall, D.1,
Watral, W.1, Seftel, M.D.1 1CancerCare Manitoba, University of Man-
itoba, Winnipeg, MB, Canada; 2Northwestern University, Chicago, IL
Background:Research studies presented in abstract formmay never
be fully published. In other areas of medicine, abstracts with positive
results are more likely to be published than negative studies, leading
to publication bias. There are limited data about the presence of pub-
lication bias in the field of blood andmarrow transplantation (BMT).
Methods: All abstracts presented at the 2006 CIBMTR/ASBMT
Tandem Meeting were categorized based on type of study (clinical
prospective or retrospective, translational, basic science, case report,
or review), and whether the results were positive, negative, or not
stated. An abstract was categorized as positive if it validated the au-
thors’ hypothesis, or if it showed that a new treatment, diagnostic
test, or procedure was useful. Two authors reviewed each abstract,
and a third author reviewed disagreements (if present). To determine
publication status, each abstract was searched on the MEDLINE
database by first and last authors.Results: 501 abstractswere reviewed. 217were published, giving a pub-
lication rate of 43%.Median time fromabstract presentation to full pub-
licationwas 19months (range 1 - 41months). 52.5%of all abstractswere
published in three journals - Biology of Blood and Marrow Transplan-
tation (19.8%), Blood (17.5%), or Bone Marrow Transplantation
(15.2%). The remaining 47.5%were published in 53 different journals,
with no one journal having more than 3% of published abstracts. Ab-
stracts that were positive were more likely to be published (50.1%)
than those that were negative (33%) or not stated (29.7%) (p5 0.001).
Clinical studies (retrospective or prospective) and translational/basic sci-
encestudiesweremore likely tobepublished thancase reportsorprimar-
ily descriptive studies (p5 0.001). Specifically, 48.5% of clinical studies
and 56.9% of basic science or translational studies were published, but
only 7.1% of descriptive or case reports were published.
Conclusion: Publication bias does exist in the field of BMT, with
positive abstracts significantly more likely to be published than neg-
ative abstracts. Full publication of negative results should be encour-
aged to provide a more balanced medical literature, and clinicians
should be aware of the existence of publication bias.PHARMACY ORAL
100
OPTIMIZING THE ROLE OF TACROLIMUS BY ACHIEVING AND MAINTAIN-
ING TARGET LEVELS VIA A LOADING DOSE FOLLOWED BY A MAINTE-
NANCE DOSE AT EMORY HEALTHCARE
Ng, A., Wilson, N.M., Surati, M., Shah, K.S., Hutcherson, D.A. Emory
Healthcare, Atlanta, GA
Purpose: Graft-versus-host disease (GVHD) is a common compli-
cation associated with allogeneic hematopoietic stem cell transplants
(HSCT). Tacrolimus plays an integral role in GVHD prophylaxis.
At Emory Healthcare, the daily intravenous dose has been 0.03
mg/kg/day based on ideal body weight. Over the last two decades,
our target tacrolimus levels have gradually changed from 10 - 40
ng/mL to 6 - 12 ng/mL. However, our dosing has remained un-
changed. Due to results of a prior evaluation demonstrating that
the majority of our patients required dose reductions based on
drug levels, we implemented a 48 hour loading dose of 0.03 mg/
kg/day followed by a 0.02 mg/kg/day maintenance dose. We have
now performed an evaluation to assess the impact of this tacrolimus
dosing strategy compared to the previously studied cohort.
Method: A retrospective chart review was conducted in allogeneic
HSCT patients who received intravenous tacrolimus from May
2008 to March 2009. Data collected included height, weight, tacro-
limus doses on days - 2 through day 1 10, and tacrolimus levels on
days 0 through day1 10. This group was compared to the previously
studied cohort receiving the standard 0.03 mg/kg dose as a control.
Result: A total of 22 patients were studied. The control group of 14
patients demonstrated an average dose adjustment of 54% (25% -
96%) on days 5, 7, and 10. The study group remained at an approx-
imate average dose of 0.02 mg/kg/day for an average of 99% (50% -
200%) of the maintenance dose. Compared with the control group
which had 100% of patients achieving levels . 12 ng/mL during
days 1 through 10, the study group resulted in approximately 36%
of patients with supratherapeutic levels. The control group had
50%of patients with levels\6 ng/mL compared to 54% in the study
group.
Oral Presentations S191Conclusion: This medication use evaluation showed that a 48 hour
load of 0.03 mg/kg/day followed by a 0.02 mg/kg/day maintenance
dose of tacrolimus demonstrated potential to optimize tacrolimus
therapy. When compared to the control group, the study group ex-
hibited fewer patients with supratherapeutic levels with no difference
in the number of patients with levels\6 ng/mL.The dosing strategy
implemented at Emory Healthcare has resulted in a greater number
of patients with tacrolimus levels within the desired range.101
CHARACTERIZATION OF BUSULFAN DOSE IN HEMATOPOIETIC STEM
CELL TRANSPLANT PATIENTS LESS THAN 12 MONTHS OF AGE
Bratcher, B.1, Held, K.2, Dalal, J.3, Liewer, S.4 1St. Louis Children’s Hos-
pital, St. Louis, MO; 2Children’s Mercy Hospital, Kansas City, MO;
3Children’s Mercy Hospital, Kansas City, MO; 4The Nebraska Medical
Center, Omaha, NE
In the pediatric population, altered busulfan pharmacokinetics
have been described in patients less than 4 years of age. Higher doses
of busulfan have been utilized to ensure therapeutic drug levels are
achieved. Patients less than 1 year of age are included in this higher
dosing strategy although the data in this population is minimal. The
purpose of this study was to characterize the dosing of patients less
than 1 year of age and compare the cumulative busulfan dose re-
ceived to that of patients between 1 and 4 years of age.
Methods: A retrospective review was performed and included six-
teen patients less than 4 years of age who received intravenous busul-
fan as part of a conditioning regimen prior to transplant. The
cumulative busulfan dose was calculated to assess the primary end-
point. Secondary endpoints included evaluation of toxicities and en-
graftment.
Results: Of the sixteen patients, ten patients were between 1 and 4
years of age and six patients were less than 1 year of age. The initial
busulfan dose was similar between groups with children less than 1
year of age receiving a mean of 0.93 mg/kg/dose (range 0.8-1 mg/
kg/dose) compared to 0.99 mg/kg/dose (range 0.8-1.28 mg/kg/
dose) in the 1-4 year group (p 5 0.4). Pharmacokinetic analysis
was performed in 15 patients (94%). Eight patients (80%) in the 1-
4 year group required an increased dose, while two patients (33%)
required a decrease in the less than 1 year group. The mean cumula-
tive busulfan dose was significantly higher in the 1-4 year group, 1.15
mg/kg/dose (range 1-1.4 mg/kg/dose) compared to 0.92mg/kg/dose
(range 0.69-1.3 mg/kg/dose) in the less than 1 year group (p5 0.01).
Engraftment and toxicities were also evaluated in this patient popu-
lation. Veno-occlusive disease was diagnosed in two patients (33.3%)
in the less than 1 year group and no cases were reported in the 1-4
year group. Engraftment was delayed in the 1-4 year group at 25
days compared to 16 days in the less than 1 year group (p 5 0.01).
Graft failure occurred in one patient (10%) in the 1-4 year group.
Conclusions: Patients less than 1 year of age required significantly
lower cumulative busulfan doses to maintain therapeutic levels com-
pared to patients in the 1-4 year age group. Strategies to optimize the
dosing of busulfan in patients less than 1 year of age warrant further
investigation.102
RETROSPECTIVE ANALYSIS OF EFFECTIVENESS OF VENO-OCCLUSIVE
PROPHYLAXIS GUIDELINES IMPLEMENTED FOR PATIENTS RECEIVING
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Ng, H.Y., Chong, M.F., Song, J.L., Tang, S., Goh, Y.T., Hwang, W.,
Linn, Y.C., Loh, Y., Diong, C. Singapore General Hospital, Singapore
Hepatic veno-occlusive disease (VOD) is a major and potentially
fatal complication of hematopoietic stem cell transplantation
(HSCT). A risk-adapted VOD prophylaxis guideline was imple-
mented in May 2008 for patients undergoing allogeneic HSCT in
Singapore General Hospital. Patients were stratified into 3 risk cat-
egories according to conditioning regimen and risk factors including
preexisting hepatitis/cirrhosis or hepatic dysfunction. Low risk pa-
tients did not receive routine VODprophylaxis, and patients at mod-
erate or high risk received ursodeoxycholic acid before conditioning
to D+21 of HSCT.Objective:This study evaluated the effectiveness of the guideline as
a tool to identify the need for routine VOD prophylaxis in patients
undergoing allogeneic HSCT. The efficacy of ursodeoxycholic
acid and risk factors associated with VOD development were also
studied.
Method:A retrospective study of patients who underwent allogeneic
HSCT between Jan 2005 and Sept 2010 was carried out where med-
ical records were reviewed. Outcomes were compared between study
group (after guidelines implementation from May 2008 to Sept
2010) and controls (before implementation of guidelines from Jan
2005 – Apr 2008). The primary outcome was the incidence of
VOD; and secondary outcome was VOD-related mortality.
Results: A total of 176 patients were included. The incidence of
VOD was 14.6% in the study group and 20% in controls (p 5
0.42). VOD did not occur in any low risk patients. In the moderate
risk category, a 10.3% reduction in VOD occurrence was associated
with routine prophylaxis (13.9% vs 24.2%). However, this difference
did not reach statistical significance (p5 0.127). Among high risk pa-
tients, the incidence was 36% in the study group and 10% in con-
trols, p 5 0.157. All except for 2 cases of VOD occurred within 21
days after HSCT. Mortality related to VOD did not differ between
the study and control group (3.1% vs. 1.3%, p 5 0.652). Prior
HSCT was identified as risk factor associated with VOD: OR,
4.44; 95% CI, 1.5-13.1; p 5 0.007.
Conclusion: The risk-adapted strategy may be effective in identify-
ing patients who may require routine VOD prophylaxis. The use of
ursodeoxycholic acid as prophylaxis resulted in a non-significant re-
duction inVODoccurrence especially inmoderate risk patients. The
high incidence of VOD among high risk patients underscores the
need for more effective prophylactic strategies. Prior HSCT should
be considered as a risk factor for future patients.103
RELATIONSHIP BETWEEN CLEARANCE OF INTRAVENOUS CALCINEURIN
INHIBITORS AND AREA UNDER THE CONCENTRATION-TIME CURVE
DECREASES DURING THE SWITCH FROM CONTINUOUS INTRAVENOUS
INFUSION TO ORAL ADMINISTRATION AFTER ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION
Watabe, D.1, Koido, K.1, Udagawa, R.1, Yokote, N.1, Kim, S.-W.2,
Mori, S.-I.2, Tanosaki, R.2, Heike, Y.2, Fukuda, T.2, Yamamoto, H.1
1National Cancer Center Hospital, Tokyo, Japan; 2National Cancer
Center Hospital, Tokyo, Japan
Background:Oral doses of cyclosporine (CSP) and tacrolimus (TAC)
are conventionally set by multiplying the doses for continuous intrave-
nous infusion by 2 and 4 respectively. It is ideal for the area under the
concentration-time curve (AUC) during oral administration (AUCpo)
to be equal to the AUC during intravenous infusion (AUCiv). In daily
clinical settings, however, we often encounter cases in which changes
in blood concentrations of these drugs deviate from expected values.
Objectives:To assess the appropriateness of conversion ratios of 1:2
for CSP and 1:4 for TAC during the switch from continuous intra-
venous infusion to oral administration by estimating rates of variabil-
ity in AUC, and to investigate factors affecting these AUC changes.
Methods: We studied patients receiving CSP or TAC who under-
went hematopoietic stem cell transplantation between April 2004
and March 2007. There were 37 patients in the CSP, and 69 in the
TAC group. First, the AUCpo/AUCiv ratio was calculated. The
AUCpo was estimated from trough concentrations using a method
described by Nakamura et al (Transplant Proc 2005; 37: 1725).
Next, the patients in each group were divided into 3 subgroups based
on AUCpo/AUCiv ratios: # 4/5; . 4/5 and\ 4/3; $ 4/3, and then
factors associated with AUC changes were investigated.
Results:Themedian value (interquartile range) of AUCpo/AUCiv in
the CSP group was 1.10 (0.79-1.39) while that in the TAC group was
0.82 (0.61-1.05). Patients who reached optimal AUCpo/AUCiv (. 4/
5 and\4/3) were 43% in theCSP group and 38% in theTACgroup.
In the CSP group, comparisons among the 3 subgroups revealed sig-
nificant differences in clearance of intravenous CSP (CLCSP) (P 5
0.019). Multivariate analysis showed that CLCSP $ 0.20 L/hr/kg
was independently associated with AUC decreases (P 5 0.027,
odds ratio 5 7.77). Similarly, in the TAC group, CL of intravenous
TAC (CLTAC) differed significantly among the 3 subgroups (P 5
0.006). Multivariate analysis in the TAC group also showed that
